Taken together, the current knowledge of TRPM2 has provided the basis for the development of pharmacologic inhibitors of TRPM2 in order to treat debilitating conditions that involve excessive cell death, including stroke, diabetes, immune disorders and inflammation. This evidence concerns the gene TRPM2 and diabetes mellitus.